CliffBio
biologic

Hizentra

Immune Globulin Subcutaneous (Human), 20% Liquid

Loss of exclusivityApril 2035projected — 12-year biologic exclusivity estimate
CompanyCSL Behring AG

Drug detail

Brand nameHizentra
Active ingredientImmune Globulin Subcutaneous (Human), 20% Liquid
Strength10G/50ML
Dosage formInjection
RouteSubcutaneous
ModalityBiologic
FDA approvalApril 2023
Marketing statusRx

More from CSL Behring AG

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the projected — 12-year biologic exclusivity estimate; estimates are projections, not legal advice.

Hizentra patent cliff — loss of exclusivity April 2035 | CliffBio